FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Alkem Labs Plant in India Cited Over OOS Investigations, Quality Systems

[ Price : $8.95]

FDA issues a 26-page Form 483 to Alkem Laboratories following an 4/20-5/1 inspection of the company's finished drug manufacturing ...

17 Revised Draft Guidances for Certain Generic Peptide Products

[ Price : $8.95]

FDA posts 17 revised draft product-specific guidances for peptide products, which it touts as a significant advancement in the age...

Final Guidance on Washout Periods in Cancer Clinical Trials

[ Price : $8.95]

FDA encourages cancer clinical trial sponsors to adopt more flexible eligibility criteria related to washout periods and concomita...

Laboratory Value-Based Eligibility Criteria in Cancer Trials Guidance

[ Price : $8.95]

A final FDA guidance urges sponsors of cancer clinical trials to broaden laboratory value-based eligibility criteria to reduce unn...

FDA to Hold Webinar on Proposed Expedited IND Pilot Program

[ Price : $8.95]

FDA announces an 8/6 educational Webinar to provide stakeholders with additional information about its proposed Expedited Investig...

Novo Nordisk Seeks Preliminary Injunction Against Lilly

[ Price : $8.95]

Novo Nordisk intensifies pressure against Eli Lilly under a motion seeking a preliminary injunction to stop Eli Lilly's misleading...

CBER Offers Tips for Cell/Gene Therapy BLA Submissions

[ Price : $8.95]

CBER recently used a virtual town hall to urge developers of cell and gene therapies to take advantage of early engagements with t...

FDA Urges Broader Eligibility for Cancer Clinical Trials

[ Price : $8.95]

An FDA final guidance encourages sponsors of oncology clinical trials to broaden eligibility criteria by including more patients w...

Reviewers Question Data on Capricor's Duchenne Cardiomyopathy Cell Therapy

[ Price : $8.95]

FDA reviewers raise issues with Capricor Therapeutics resubmitted deramiocel for treating cardiomyopathy in male patients with Duc...

Amgen New Data Pushes Back Against Proposal to Withdraw Tavneos

[ Price : $8.95]

Amgen files new scientific data and analyses in its bid to prevent FDA withdrawal of Tavneos (avacopan), arguing that the treatmen...